Karyopharm Therapeutics AI Stock Analysis
Want to see KPTIQ full AI Analyst Report?
Karyopharm Therapeutics (KPTIQ) AI Stock Analysis
Karyopharm Therapeutics
(Other OTC:KPTIQ)
The score is primarily driven down by very weak financial performance (persistent large losses, negative equity, ongoing cash burn) and extremely bearish technicals (price far below major moving averages with negative momentum). The earnings call provides some offset from meaningful clinical/regulatory progress and reaffirmed guidance, but near-term funding/covenant risk remains a dominant overhang, and valuation metrics provide little support given continued losses and no dividend.
Karyopharm Therapeutics Key Performance Indicators (KPIs)
Revenue by TypeSeparates sales into product revenue, collaboration and licensing income, milestones, royalties, and other sources to show what actually drives cash flow. Reveals whether the company’s income is coming from repeatable drug sales (commercial traction for XPOVIO) or from irregular, one-time partner payments—key for judging predictability, growth sustainability, and runway risk.
Product revenue functions as the recurring backbone (XPOVIO): it dipped in early‑2025 then recovered to prior peaks, while License & Other is lumpy and driven by sporadic one‑off deals. Management warns the recent top‑line uplift was largely gross‑to‑net dynamics, not steady demand, and cash runway into late Q3 2026 means upcoming clinical readouts or financing are likely catalysts—model product growth conservatively and treat license receipts and gross‑to‑net improvements as non‑recurring upside.
The FlyKaryopharm Therapeutics (KPTIQ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $394.66K
- Dividend Yield
- ―
- Average Volume (3M)
- 8.47M
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 2.45
- Revenue Growth
- 6.81%
- EPS Growth
- 11.95%
- Country
- US
- Employees
- 228
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Karyopharm Therapeutics Business Overview & Revenue Model
Company Description
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating...
How the Company Makes Money
Karyopharm generates revenue primarily from (1) net product sales of XPOVIO (selinexor) in territories where it commercializes the drug directly, and (2) collaboration-related revenue from partners that commercialize selinexor in licensed territories...
Karyopharm Therapeutics Financial Statement Overview
Summary
Financial statements are highly stressed: revenue is flat to slightly down (TTM ~-3%) and the company remains deeply unprofitable (TTM net margin ~-153%) despite very high gross margins (~96%). The balance sheet is a major risk with deeply negative equity (~-$330M TTM) and meaningful debt (~$216M) relative to a small asset base (~$111M). Cash flow is still materially negative (TTM FCF ~-$65M) though burn has improved versus prior periods, implying continued reliance on external funding.
Income Statement
18Very NegativeBalance Sheet
9Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 146.62M | 146.07M | 145.24M | 146.03M | 157.07M | 209.82M |
| Gross Profit | 140.58M | 140.12M | 139.23M | 141.09M | 151.86M | 206.42M |
| EBITDA | -175.85M | -149.85M | -38.60M | -118.42M | -139.31M | -96.98M |
| Net Income | -224.74M | -196.04M | -76.42M | -143.10M | -165.29M | -124.09M |
Balance Sheet | ||||||
| Total Assets | 111.32M | 108.42M | 164.42M | 240.44M | 358.17M | 305.31M |
| Cash, Cash Equivalents and Short-Term Investments | 65.11M | 63.74M | 108.71M | 191.44M | 277.97M | 228.62M |
| Total Debt | 215.88M | 233.61M | 194.52M | 177.02M | 179.07M | 180.58M |
| Total Liabilities | 441.49M | 401.34M | 350.44M | 376.64M | 374.83M | 384.98M |
| Stockholders Equity | -330.17M | -292.93M | -186.02M | -136.21M | -16.66M | -79.67M |
Cash Flow | ||||||
| Free Cash Flow | -65.35M | -75.37M | -127.63M | -92.72M | -149.67M | -112.83M |
| Operating Cash Flow | -65.35M | -75.37M | -127.49M | -92.72M | -149.55M | -107.12M |
| Investing Cash Flow | 2.97M | 43.38M | 95.47M | 7.94M | -104.26M | 141.84M |
| Financing Cash Flow | 78.60M | 30.05M | 41.65M | 1.12M | 193.74M | 73.65M |
Karyopharm Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTIQ, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.92, and below the 200-day MA of 5.78, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 28.06 is Positive, neither overbought nor oversold. The STOCH value of 0.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPTIQ.
Karyopharm Therapeutics Risk Analysis
Karyopharm Therapeutics disclosed 74 risk factors in its most recent earnings report. Karyopharm Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksKaryopharm Therapeutics Peers Comparison
Overall Rating
ATNM65.75Neutral
IPSC50Neutral
MDCX48Neutral
LTRN44Neutral- KPTIQ40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ATNM | 66Neutral | $49.36M | 4.42 | 83.42% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| IPSC | 50Neutral | $304.21M | -1.67 | -52.76% | ― | -100.00% | -219.52% |
| MDCX | 48Neutral | $3.52M | -0.03 | 1594.83% | ― | ― | 37.61% |
| LTRN | 44Neutral | $6.92M | -0.30 | -456.35% | ― | ― | 9.68% |
| KPTIQ | 40Underperform | $394.66K | 0.00 | 77.63% | ― | 6.81% | 11.95% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KPTIQ | Karyopharm Therapeutics INC | 0.02 | -5.48 | -99.69% | |
| ATNM | Actinium Pharmaceuticals | 1.59 | 0.34 | 27.20% | |
| LTRN | Lantern Pharma, Inc. | 0.48 | -2.98 | -86.10% | |
| IPSC | Century Therapeutics, Inc. | 1.74 | 1.28 | 275.00% | |
| MDCX | Medicus Pharma Ltd | 1.64 | -111.36 | -98.55% |
Karyopharm Therapeutics Corporate Events
Karyopharm Therapeutics Announces Nasdaq Delisting Following Bankruptcy Filing
NegativeKaryopharm Therapeutics said on November 4, 2026, that Nasdaq had determined its securities would be delisted after the company and subsidiary KPT Texas LLC filed Chapter 11 petitions on November 2. The company said it would not appeal the decision.N...
Karyopharm Therapeutics Files for Chapter 11 Bankruptcy Protection
NegativeOn November 2, 2026, Karyopharm Therapeutics and subsidiary KPT Texas LLC filed voluntary Chapter 11 petitions in Texas and placed their operations under court jurisdiction as debtors-in-possession. They requested joint administration and sought firs...
Karyopharm Announces Restructuring Agreement and Chapter 11 Filing
NegativeOn November 2, 2026, Karyopharm announced that it had entered into a Restructuring Support Agreement with existing lenders, noteholders and other stakeholders, providing for a merger between Ayrmid Ltd. and a reorganized Karyopharm. The company also...
Karyopharm Extends Forbearance Agreement to November 1, 2026
NeutralKaryopharm Therapeutics Inc. disclosed that it had previously entered into a Forbearance Agreement and Limited Waiver to certain indentures on September 10, 2026, with details reported in filings on September 11, 2026 and October 14, 2026. The agreem...
Karyopharm Issues Convertible Preferred Stock, Alters Capital Structure
NeutralOn September 10, 2026, Karyopharm Therapeutics entered into a Forbearance Agreement and Limited Waiver to Indentures and a related fee agreement, choosing to satisfy $20 million of fees through equity rather than cash to preserve liquidity while adva...
Karyopharm Faces Liquidity Crisis Under Forbearance Agreement
NegativeOn September 10, 2026, Karyopharm entered a forbearance agreement and limited waiver with its lenders, convertible noteholders and royalty financing investors after failing to pay a $15.8 million term-loan installment and certain interest on its debt...
Karyopharm Seeks Accelerated FDA Approval for XPOVIO Combo
PositiveOn August 31, 2026, Karyopharm Therapeutics Inc. said it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026